kynurenine has been researched along with Cerebral Malaria in 7 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "CSF kynurenine and KYNA were compared to CSF cytokine levels, acute and long-term neurologic complications, and long-term cognitive impairments." | 5.46 | Cerebrospinal fluid kynurenine and kynurenic acid concentrations are associated with coma duration and long-term neurocognitive impairment in Ugandan children with cerebral malaria. ( Bangirana, P; Engberg, G; Färnert, A; Franzén-Röhl, E; Holmberg, D; Idro, R; John, CC; Opoka, RO; Schwieler, L; Sellgren, CM; Wickström, R, 2017) |
| "Cerebral malaria is a life-threatening complication of malaria caused by the parasite Plasmodium falciparum." | 2.61 | Blood-Brain Barrier in Cerebral Malaria: Pathogenesis and Therapeutic Intervention. ( Nishanth, G; Schlüter, D, 2019) |
| "CSF kynurenine and KYNA were compared to CSF cytokine levels, acute and long-term neurologic complications, and long-term cognitive impairments." | 1.46 | Cerebrospinal fluid kynurenine and kynurenic acid concentrations are associated with coma duration and long-term neurocognitive impairment in Ugandan children with cerebral malaria. ( Bangirana, P; Engberg, G; Färnert, A; Franzén-Röhl, E; Holmberg, D; Idro, R; John, CC; Opoka, RO; Schwieler, L; Sellgren, CM; Wickström, R, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Holmberg, D | 1 |
| Franzén-Röhl, E | 1 |
| Idro, R | 1 |
| Opoka, RO | 1 |
| Bangirana, P | 1 |
| Sellgren, CM | 1 |
| Wickström, R | 1 |
| Färnert, A | 1 |
| Schwieler, L | 1 |
| Engberg, G | 1 |
| John, CC | 1 |
| Bastos, MF | 1 |
| Kayano, ACAV | 1 |
| Silva-Filho, JL | 1 |
| Dos-Santos, JCK | 1 |
| Judice, C | 1 |
| Blanco, YC | 1 |
| Shryock, N | 1 |
| Sercundes, MK | 1 |
| Ortolan, LS | 1 |
| Francelin, C | 1 |
| Leite, JA | 1 |
| Oliveira, R | 1 |
| Elias, RM | 1 |
| Câmara, NOS | 1 |
| Lopes, SCP | 1 |
| Albrecht, L | 1 |
| Farias, AS | 1 |
| Vicente, CP | 1 |
| Werneck, CC | 1 |
| Giorgio, S | 1 |
| Verinaud, L | 1 |
| Epiphanio, S | 1 |
| Marinho, CRF | 1 |
| Lalwani, P | 1 |
| Amino, R | 1 |
| Aliberti, J | 1 |
| Costa, FTM | 1 |
| Nishanth, G | 1 |
| Schlüter, D | 1 |
| Miu, J | 1 |
| Ball, HJ | 1 |
| Mellor, AL | 1 |
| Hunt, NH | 3 |
| Medana, IM | 2 |
| Day, NP | 2 |
| Salahifar-Sabet, H | 1 |
| Stocker, R | 2 |
| Smythe, G | 2 |
| Bwanaisa, L | 1 |
| Njobvu, A | 1 |
| Kayira, K | 1 |
| Turner, GD | 2 |
| Taylor, TE | 1 |
| Clark, CJ | 1 |
| Mackay, GM | 1 |
| Smythe, GA | 1 |
| Bustamante, S | 1 |
| Stone, TW | 1 |
| Phillips, RS | 1 |
| Hien, TT | 1 |
| Phu, NH | 1 |
| Mai, NT | 1 |
| Chu'ong, LV | 1 |
| Chau, TT | 1 |
| Taylor, A | 1 |
| Salahifar, H | 1 |
| Farrar, J | 1 |
| White, NJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An MRI Ancillary Study of a Malaria Fever Randomized Controlled Trial (RCT)[NCT05746819] | 256 participants (Anticipated) | Observational | 2021-01-02 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for kynurenine and Cerebral Malaria
| Article | Year |
|---|---|
Blood-Brain Barrier in Cerebral Malaria: Pathogenesis and Therapeutic Intervention.
Topics: Animals; Antimalarials; Blood-Brain Barrier; Cell-Derived Microparticles; Disease Models, Animal; Dr | 2019 |
2 trials available for kynurenine and Cerebral Malaria
| Article | Year |
|---|---|
Metabolites of the kynurenine pathway of tryptophan metabolism in the cerebrospinal fluid of Malawian children with malaria.
Topics: Adult; Child; Child, Preschool; Disease Progression; Humans; Kynurenine; Malaria, Cerebral; Malawi; | 2003 |
The clinical significance of cerebrospinal fluid levels of kynurenine pathway metabolites and lactate in severe malaria.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Artemether; Artemisinins; Humans; Kynurenine; Lacta | 2002 |
4 other studies available for kynurenine and Cerebral Malaria
| Article | Year |
|---|---|
Cerebrospinal fluid kynurenine and kynurenic acid concentrations are associated with coma duration and long-term neurocognitive impairment in Ugandan children with cerebral malaria.
Topics: Child; Child, Preschool; Cognition; Coma; Female; Humans; Infant; Kynurenic Acid; Kynurenine; Malari | 2017 |
Inhibition of hypoxia-associated response and kynurenine production in response to hyperbaric oxygen as mechanisms involved in protection against experimental cerebral malaria.
Topics: Animals; Brain; Cerebrovascular Circulation; Endothelial Cells; Female; Hyperbaric Oxygenation; Hypo | 2018 |
Effect of indoleamine dioxygenase-1 deficiency and kynurenine pathway inhibition on murine cerebral malaria.
Topics: Animals; Brain; Enzyme Inhibitors; Female; Gas Chromatography-Mass Spectrometry; Humans; Indoleamine | 2009 |
Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition.
Topics: Animals; Chemokine CCL4; Disease Models, Animal; Kynurenine; Kynurenine 3-Monooxygenase; Macrophage | 2005 |